10-K: Rein Therapeutics Faces Going Concern Doubt, Pauses LTI-01 Amid Funding Crunch

Rein Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses and raised substantial doubt about its ability to continue as a going concern, leading to an indefinite pause in LTI-01 and preclinical programs.

Summary

• Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for orphan pulmonary and fibrosis indications.
• The lead product candidate, LTI-03, is in Phase 2 clinical development for Idiopathic Pulmonary Fibrosis (IPF).
• Development of LTI-01 and all preclinical programs has been paused indefinitely due to insufficient funding.
• The company reported a net loss of $49.9 million for the fiscal year ended December 31, 2025, compared to $62.9 million for 2024.
• An accumulated deficit of $401.3 million was reported as of December 31, 2025.
• Cash and cash equivalents were $3.2 million as of December 31, 2025, which, combined with $4.3 million from 2026 bridge loans, is only sufficient to fund operations into the second quarter of 2026.
• Management has raised substantial doubt about the company's ability to continue as a going concern.
• Screening and recruitment for the RENEW Phase 2 clinical trial of LTI-03 initiated in May 2025, with the first patient dosed in March 2026.
• Initial interim topline data for the LTI-03 Phase 2 trial is expected in the fourth quarter of 2026.
• Material weaknesses in internal control over financial reporting were identified for both 2025 and 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with significant concern due to the explicit 'going concern' warning, substantial accumulated losses, and the indefinite halt of multiple development programs, despite some positive early-stage clinical data for LTI-03. The company's future is highly speculative and dependent on uncertain capital raises.

Positives

• LTI-03 Phase 1b data showed positive trends in 7 out of 8 biomarkers, with statistically significant decreases in GAL-7 (p=0.0014), TSLP (p=0.0223), and Col-11 (p=0.0489) in Cohort 1, supporting its potential to reduce fibrosis and inflammation.
• LTI-03 stimulated production of solRAGE, a factor indicative of type I epithelial cell health, which is a critical and largely unaddressed aspect of IPF.
• LTI-03 Phase 1b Cohort 2 demonstrated dose-dependent trends in five biomarkers (COL1A1, CXCL7, TSLP, GAL-7, and SPD), providing evidence of active pharmacodynamics.
• LTI-03 reduced SPD by 5% in Phase 1b Cohort 2, which compares to nintedanib's 4% reduction in the INMARK trial, though direct comparability is limited due to different trial designs.
• LTI-03 was generally well-tolerated in both Phase 1a and Phase 1b trials, with no serious adverse events reported.
• LTI-03 has received Orphan Drug Designation in both the U.S. and the European Union for the treatment of IPF.
• LTI-01 has received Orphan Drug Designation in the U.S. and EU for empyema and Fast Track Designation in the U.S. for infected, non-draining pleural effusion.
• The RENEW Phase 2 clinical trial for LTI-03 has initiated screening and recruitment, with regulatory authorization obtained from the EMA (Germany, Poland) and the UK's MHRA.
• The first patient in the RENEW Phase 2 clinical trial of LTI-03 was dosed in March 2026.
• Secured $4.3 million in net proceeds from unsecured promissory notes (bridge loans) in January and February 2026.

Negatives

• Incurred significant net losses of $49.9 million for FY2025 and $62.9 million for FY2024.
• Reported an accumulated deficit of $401.3 million as of December 31, 2025.
• Management has raised substantial doubt about the company's ability to continue as a going concern beyond the second quarter of 2026.
• Existing cash and cash equivalents, even with recent bridge loan proceeds, are insufficient to complete the Phase 2 RENEW clinical trial of LTI-03.
• Development activities for LTI-01 and all preclinical programs (cystic fibrosis, systemic fibrosis) have been paused indefinitely due to current capital limitations, resulting in a $28.7 million impairment loss on intangible assets in 2025.
• Identified material weaknesses in internal control over financial reporting for both December 31, 2025, and December 31, 2024, indicating deficiencies in accounting personnel and procedures.
• LTI-03 Phase 1a clinical trial experienced moderate to severe treatment-emergent adverse events (TEAEs) such as wheezing, chest tightness, and decline in forced expiratory volume at higher doses, leading to a study hold.
• LTI-01 Phase 2a trial did not achieve statistical significance on its primary endpoint of treatment failure.
• The company has no products approved for commercial sale and has not generated any revenue from product sales since inception.
• Reliance on third-party manufacturing and supply vendors without long-term agreements poses supply chain risks.

Risks

• Require substantial additional capital to finance operations beyond Q2 2026 and to complete the development and commercialization of product candidates.
• Inability to raise sufficient capital on acceptable terms may force delays, reductions, or elimination of research and development programs and future commercialization efforts.
• Identified material weaknesses in internal control over financial reporting may result in material misstatements of financial statements or failure to meet periodic reporting obligations.
• Significant net losses since inception and expected to continue, raising substantial doubt about the ability to continue as a going concern.
• Business is highly dependent on the success of LTI-03; safety or efficacy problems, development delays, or regulatory issues would significantly harm development plans.
• The approach to drug research and development in fibrotic diseases, focusing on Cav1-related peptides, is unproven and may not result in marketable products.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results do not necessarily predict final results.
• May incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of LTI-03.
• Future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in earlier studies, potentially delaying or preventing regulatory approval.
• Clinical development is a lengthy, complex, and expensive process with an uncertain outcome.
• Never obtained marketing approval for a product candidate and may be unable to obtain, or be delayed in obtaining, marketing approval for any product candidate.
• Reliance on third parties to conduct certain aspects of clinical trials and preclinical studies; failure to perform could delay or prevent regulatory approval.
• Reliance on third-party manufacturing and supply vendors; supply may become limited, interrupted, or of unsatisfactory quality.
• Difficulty and cost in protecting proprietary intellectual property rights and technology, with no assurance of protection.
• Concentration of ownership by entities and individuals affiliated with Bios Partners could exert substantial influence over the business.
• Internal computer systems, or those of vendors, may fail or suffer security breaches, disrupting product development programs.
• Failure to maintain compliance with Nasdaq Capital Market listing requirements could result in delisting, adversely affecting liquidity.
• The price of common stock may be volatile, and investors could lose all or part of their investment.
• Changes in tax laws or their implementation/interpretation may adversely affect the business and financial condition.
• Limited foreign intellectual property rights may hinder protection of inventions throughout the world.
• Dependence on sole-source third-party suppliers for critical materials could lead to supply disruptions.

Future Outlook

The company expects to report initial interim topline data on some proportion of patients in the RENEW Phase 2 clinical trial of LTI-03 in the fourth quarter of 2026. Future viability is dependent on raising substantial additional capital to fund operations beyond Q2 2026 and complete the development and commercialization of LTI-03. The timing and likelihood of resuming development for LTI-01 and preclinical programs are uncertain and contingent on obtaining additional financing and the future success of LTI-03.

Management Comments

• Management believes that existing cash and cash equivalents, together with proceeds from 2026 bridge loans, will fund planned operating expenses and capital expenditure requirements into the second quarter of 2026.
• Management acknowledges that these funds are not sufficient to complete the Phase 2 RENEW clinical trial of LTI-03 and additional funding will be required.
• Management has decided to pause development activities related to LTI-01 and preclinical programs for an indefinite period due to current capital limitations, prioritizing LTI-03.
• Management is implementing procedures to remediate identified material weaknesses in internal control over financial reporting, including enhancing risk assessment, integrating acquired systems, engaging third-party assistance, and reassessing staffing.

Industry Context

StockSavvy.ai notes that Rein Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on orphan pulmonary and fibrosis indications. While the company's Cav1-related peptide approach for LTI-03 is novel and unique compared to most existing or investigational therapies, it faces significant competition from larger pharmaceutical companies with greater resources such as AbbVie Inc., Boehringer Ingelheim GmbH (marketers of Ofev and Jascayd), Bristol Myers Squibb Company, Gilead Sciences, Inc., Roche Holding AG (marketer of Esbriet and tPA/DNase for off-label LPE), and Novartis AG. The indefinite pause of LTI-01 and preclinical programs due to funding constraints highlights the significant financial pressures faced by smaller clinical-stage biotechs in bringing novel therapies to market, especially in orphan indications where patient populations are small but development costs remain high.

Comparison to Industry Standards

• LTI-03's 5% reduction in SPD (an indicator of epithelial cell health linked to lung function decline) in Phase 1b Cohort 2 compares favorably to nintedanib's 4% reduction in SPD observed in the third-party INMARK trial over 12 weeks.
• The company explicitly states that the comparison between LTI-03's Phase 1b trial and the INMARK trial for nintedanib involves different trial designs, patient enrollment criteria, treatment regimens, and measurement time periods, making direct comparability uncertain.
• For loculated pleural effusion (LPE), LTI-01 aims to replace off-label intrapleural fibrinolytic therapy (IPFT) using tissue plasminogen activator (tPA) in combination with recombinant deoxyribonuclease (DNase), which is the current off-label standard of care (manufactured by Roche Holding AG).
• LTI-01's demonstrated relative resistance to Plasminogen Activator Inhibitor-1 (PAI-1) inhibition suggests potential advantages in terms of longer duration of activity, eliminating the need for repeated daily dosing, and potentially conferring a lower risk of bleeding compared to tPA.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May be subject to various legal proceedings and claims that arise in the ordinary course of business, which could have a material adverse impact due to defense and settlement costs, diversion of management resources, and other factors.

Related Party Transactions

• Entities and individuals affiliated with Bios Equity Partners, LP (Bios Partners) beneficially owned 7.11% of the company's outstanding common stock as of March 24, 2026.
• Bios Partners participated in the April 2025 Warrant Exchanges, surrendering PIPE Warrants for 1,300,500 shares and providing $2.1 million cash for Exchange Pre-Funded Warrants.
• An entity affiliated with Bios Partners purchased additional pre-funded warrants for 312,695 shares in a private placement for $0.5 million.
• Assuming the conversion of all outstanding Series X Preferred Stock and the exercise of outstanding warrants, options, and other rights, Bios Entities would own 38.4% of common stock on a fully diluted basis as of March 24, 2026, potentially exerting substantial influence over the business.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity offerings, potential for stock price decline due to going concern doubt, volatility, and program delays. The concentration of ownership by Bios Partners could also impact control.
• Employees face uncertainty regarding job security due to financial constraints and program pauses. The value of stock-based compensation is tied to the company's stock performance.
• Patients with loculated pleural effusion (LPE), cystic fibrosis, and systemic fibrosis indications will experience delayed or halted access to potential therapies due to the indefinite pause of LTI-01 and preclinical programs.
• Creditors and suppliers face increased risk due to the company's going concern status and its ongoing need for additional financing.
• Licensors (e.g., UT System, MUSC, Vivarta) may see potential impacts on future milestone and royalty payments if product development is delayed or halted.

Next Steps

• Obtain sufficient additional funding to sustain operations beyond Q2 2026 and complete the Phase 2 RENEW clinical trial of LTI-03.
• Report initial interim topline data on some proportion of patients in the RENEW Phase 2 clinical trial of LTI-03 in the fourth quarter of 2026.
• Continue to implement remediation plans for identified material weaknesses in internal control over financial reporting in fiscal year 2026.
• Activate additional sites and enroll patients for the RENEW trial throughout the U.S., UK, Europe, and other jurisdictions.
• Potentially investigate LTI-01 in an additional Phase 2 dose-ranging, placebo-controlled clinical trial with a lower dose, contingent on additional funding.
• Resume development activities for preclinical programs targeting cystic fibrosis and systemic fibrosis indications, contingent on additional financing.

Key Dates

Recommendation

Rein Therapeutics faces severe financial distress, explicitly stating 'substantial doubt about its ability to continue as a going concern' beyond Q2 2026. The indefinite pause of LTI-01 and all preclinical programs, coupled with significant accumulated losses and material weaknesses in internal controls, indicates a highly precarious financial position. While LTI-03 shows some promise and is in Phase 2, the company lacks sufficient funding to complete this trial, making its future highly speculative and dependent on uncertain capital raises. This level of financial instability and operational curtailment warrants a strong sell recommendation for investors.

Keywords

Rein Therapeutics, RNTX, Biopharmaceutical, Clinical Stage, Idiopathic Pulmonary Fibrosis, IPF, LTI-03, Fibrotic Diseases, Orphan Drug, Drug Development, Clinical Trials, Going Concern, SEC Filing, 10-K, Biotech, Cav1-related peptides, Pulmonary Fibrosis, LTI-01, Loculated Pleural Effusion